153 related articles for article (PubMed ID: 27911280)
21. Prognostic value of Wnt inhibitory factor-1 expression in hepatocellular carcinoma that is independent of gene methylation.
Huang L; Li MX; Wang L; Li BK; Chen GH; He LR; Xu L; Yuan YF
Tumour Biol; 2011 Feb; 32(1):233-40. PubMed ID: 21052890
[TBL] [Abstract][Full Text] [Related]
22. Frequent hypermethylation of WNT pathway genes in laryngeal squamous cell carcinomas.
Paluszczak J; Hemmerling D; Kostrzewska-Poczekaj M; Jarmuż-Szymczak M; Grenman R; Wierzbicka M; Baer-Dubowska W
J Oral Pathol Med; 2014 Oct; 43(9):652-7. PubMed ID: 24762262
[TBL] [Abstract][Full Text] [Related]
23. Frequent epigenetic inactivation of deleted in lung and esophageal cancer 1 gene by promoter methylation in non-small-cell lung cancer.
Zhang Y; Miao Y; Yi J; Wang R; Chen L
Clin Lung Cancer; 2010 Jul; 11(4):264-70. PubMed ID: 20630829
[TBL] [Abstract][Full Text] [Related]
24. The clinicopathological significance and potential drug target of E-cadherin in NSCLC.
Zhong K; Chen W; Xiao N; Zhao J
Tumour Biol; 2015 Aug; 36(8):6139-48. PubMed ID: 25758052
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathological significance of DAPK promoter methylation in non-small-cell lung cancer: a systematic review and meta-analysis.
Zhang Y; Wu J; Huang G; Xu S
Cancer Manag Res; 2018; 10():6897-6904. PubMed ID: 30588095
[TBL] [Abstract][Full Text] [Related]
26. The negative regulators of Wnt pathway-DACH1, DKK1, and WIF1 are methylated in oral and oropharyngeal cancer and WIF1 methylation predicts shorter survival.
Paluszczak J; Sarbak J; Kostrzewska-Poczekaj M; Kiwerska K; Jarmuż-Szymczak M; Grenman R; Mielcarek-Kuchta D; Baer-Dubowska W
Tumour Biol; 2015 Apr; 36(4):2855-61. PubMed ID: 25487617
[TBL] [Abstract][Full Text] [Related]
27. Clinical significance of DAPK promoter hypermethylation in lung cancer: a meta-analysis.
Li Y; Zhu M; Zhang X; Cheng D; Ma X
Drug Des Devel Ther; 2015; 9():1785-96. PubMed ID: 25848215
[TBL] [Abstract][Full Text] [Related]
28. Correlation Between RASSF1A Gene Promoter Hypermethylation in Serum or Sputum and Non-Small Cell Lung Cancer (NSCLC): A Meta-Analysis.
Zhang Z; Yan S; Cui H; Chen H; Liu J
Med Sci Monit; 2019 Jul; 25():5518-5524. PubMed ID: 31342946
[TBL] [Abstract][Full Text] [Related]
29. Promoter methylation of WNT inhibitory factor-1 may be associated with the pathogenesis of multiple human tumors.
Zhou Y; Li Z; Ding Y; Zhang P; Wang J; Zhang J; Wang H
J Cancer Res Ther; 2018 Jun; 14(Supplement):S381-S387. PubMed ID: 29970693
[TBL] [Abstract][Full Text] [Related]
30. The prognostic value of epigenetic silencing of p16 gene in NSCLC patients: a systematic review and meta-analysis.
Lou-Qian Z; Rong Y; Ming L; Xin Y; Feng J; Lin X
PLoS One; 2013; 8(1):e54970. PubMed ID: 23372805
[TBL] [Abstract][Full Text] [Related]
31. The EPHB6 receptor tyrosine kinase is a metastasis suppressor that is frequently silenced by promoter DNA hypermethylation in non-small cell lung cancer.
Yu J; Bulk E; Ji P; Hascher A; Tang M; Metzger R; Marra A; Serve H; Berdel WE; Wiewroth R; Koschmieder S; Müller-Tidow C
Clin Cancer Res; 2010 Apr; 16(8):2275-83. PubMed ID: 20371680
[TBL] [Abstract][Full Text] [Related]
32. Hypermethylation of RUNX3 but not WIF1 gene and its association with stage and nodal status of tongue cancers.
Supic G; Kozomara R; Jovic N; Zeljic K; Magic Z
Oral Dis; 2011 Nov; 17(8):794-800. PubMed ID: 21819494
[TBL] [Abstract][Full Text] [Related]
33. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
[TBL] [Abstract][Full Text] [Related]
34. The clinicopathological significance and drug target potential of FHIT in breast cancer, a meta-analysis and literature review.
Su Y; Wang X; Li J; Xu J; Xu L
Drug Des Devel Ther; 2015; 9():5439-45. PubMed ID: 26491255
[TBL] [Abstract][Full Text] [Related]
35. DNA methylation of hMLH1 correlates with the clinical response to cisplatin after a surgical resection in Non-small cell lung cancer.
Wu F; Lu M; Qu L; Li DQ; Hu CH
Int J Clin Exp Pathol; 2015; 8(5):5457-63. PubMed ID: 26191250
[TBL] [Abstract][Full Text] [Related]
36. Procaine and procainamide inhibit the Wnt canonical pathway by promoter demethylation of WIF-1 in lung cancer cells.
Gao Z; Xu Z; Hung MS; Lin YC; Wang T; Gong M; Zhi X; Jablons DM; You L
Oncol Rep; 2009 Dec; 22(6):1479-84. PubMed ID: 19885602
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of apoptosis-associated speck-like protein containing a CARD gene promoter methylation in resectable non-small-cell lung cancer.
Zhang Z; Tan S; Zhang L
Clin Lung Cancer; 2006 Jul; 8(1):62-5. PubMed ID: 16870048
[TBL] [Abstract][Full Text] [Related]
38. CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients.
Bradly DP; Gattuso P; Pool M; Basu S; Liptay M; Bonomi P; Buckingham L
Diagn Mol Pathol; 2012 Dec; 21(4):207-13. PubMed ID: 23111194
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway.
Urakami S; Shiina H; Enokida H; Kawakami T; Tokizane T; Ogishima T; Tanaka Y; Li LC; Ribeiro-Filho LA; Terashima M; Kikuno N; Adachi H; Yoneda T; Kishi H; Shigeno K; Konety BR; Igawa M; Dahiya R
Clin Cancer Res; 2006 Jan; 12(2):383-91. PubMed ID: 16428476
[TBL] [Abstract][Full Text] [Related]
40. CHFR hypermethylation and EGFR mutation are mutually exclusive and exhibit contrastive clinical backgrounds and outcomes in non-small cell lung cancer.
Koga T; Takeshita M; Yano T; Maehara Y; Sueishi K
Int J Cancer; 2011 Mar; 128(5):1009-17. PubMed ID: 20473935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
